FactaeThe Factual News

GLP-1 agonists face prescription challenges in clinical practice

Anti-obesity drugs like GLP-1 agonists struggle to become routine.

Published 2h1 sourceNotableupdated 1h
Lire en français
≈ 13s

The fact

Doctors lack guidelines for dosing and patient monitoring.

This therapeutic class remains underused despite proven efficacy.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Follow topic →
Auto-synthesis from 1 media source · identified on September 25, 2026
← Back to home
Discover

Read more

All sante →
sante

GLP-1 agonists now reimbursed in France outside obesity treatment

17sem · 1 sourcesante

GLP-1 agonists linked to non-gastrointestinal side effects

1sem · 1 sourcesante

Anti-obesity GLP-1 drugs: general practitioners excluded from prescribing

16sem · 1 sourcesante

Obesity treatments: weight regain after aGLP-1 drugs raises concerns

1sem · 1 sourcesante

Growing overdose risks with GLP-1 agonists

19sem · 1 sourcescience

Anti-obesity drugs: Scientists investigate why they fail in some patients

19h · 1 source